On the origins of the androgen receptor low molecular weight species

Maria Mudryj1, Clifford G Tepper

  • 1Veterans Affairs-Northern California Health Care System, Mather, CA 95655, USA. mmudryj@ucdavis.edu

Hormones & Cancer
|July 18, 2013
PubMed

Insights

Castration-resistant prostate cancer (CaP) progresses due to androgen receptor (AR) activity. This review details novel, ligand-independent AR variants driving CaP proliferation and treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer (CaP) is a common malignancy effectively treated by androgen ablation.
  • However, castration-resistant prostate cancer (CRPC) emerges, becoming refractory to therapies.
  • CRPC remains reliant on androgen receptor (AR) expression despite lacking dependence on physiological androgens.

Purpose of the Study:

  • To review mechanisms by which prostate cancer cells circumvent androgen ablation therapies.
  • To focus on the role of low molecular weight AR species lacking a ligand-binding domain.
  • To discuss the etiology, biological activity, and therapeutic implications of these novel AR isoforms.

Main Methods:

  • Literature review of studies on prostate cancer and androgen receptor signaling.
  • Analysis of mechanisms contributing to castration resistance.
  • In-depth discussion of specific AR isoforms and their functional characteristics.

Main Results:

  • Multiple mechanisms allow CaP cells to resist androgen ablation, including AR mutations, overexpression, and altered co-activator function.
  • A key mechanism involves the expression of low molecular weight AR species that lack the ligand-binding domain.
  • These AR variants function independently of androgens to drive tumor proliferation.

Conclusions:

  • Novel androgen receptor isoforms lacking a ligand-binding domain represent a significant mechanism of castration resistance in prostate cancer.
  • Understanding these AR variants is crucial for developing new therapeutic strategies.
  • These isoforms may serve as predictive biomarkers and therapeutic targets for advanced prostate cancer.

Related Concept Videos

Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
Types of Receptors: Internal Receptors01:07

Types of Receptors: Internal Receptors

Many cellular signals are hydrophilic and cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind intracellular receptors that reside within the cell cytoplasm or nucleus. Many mammalian steroid hormones and nitric oxide (NO) gas use this cell signaling mechanism.
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
Intracellular Hormone Receptors01:08

Intracellular Hormone Receptors

Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...